Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* Male and female patients aged ≥ 19 years old~* Chronic renal failure; 2 months stable on PD~* no peritonitis within the previous 2 months~* Without severe concomitant disease~* Negative pregnancy test in female patients of childbearing potential and adequate contraception in female patients of childbearing age~Exclusion Criteria:~* Known hypersensitivity to study medication~* Treatment with another investigational drug within 1 month prior to start of study medication~* Malignancy requiring chemotherapy or radiation~* Pregnancy or nursing,~* Presumed non-compliance~* Limited efficacy of peritoneal dialysis due to anatomical anomalies or severe intra-abdominal adhesions~* Clinical significant inflammatory parameters~* Less than 50 kg body weight~* Immunosuppressive therapy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
- Arm B (Type: OTHER): Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.

Based on this trial design, predict the completion outcome and termination type (if applicable).